Market research
2I3.F Champions Oncology, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 60M
- P/E ratio
- Not available
- Analyst target
- 15.67
- Dividend yield
- Not available
- Beta
- 0.4
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15870P3073
- Market cap
- 60M
- P/E ratio
- Not available
- Analyst target
- 15.67
- Dividend yield
- Not available
- Beta
- 0.4
About
About Champions Oncology, Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2I3.F discussion.
5 years, 5 months ago
Champions Oncology, Inc is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Champions Oncology, Inc's total revenue rose by 20.0% to $11M since the same quarter in the previous year.
Its net income has increased by 81.8% to $740K since the same quarter in the previous year.
Finally, its free cash flow fell by 1088.9% to $-1M since the same quarter in the previous year.
Based on the above factors, Champions Oncology, Inc gets an overall score of 3/5.